Moderna will soon learn the regulatory fate of its mRNA-based flu shot.

The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.

(Image credit: Maddie Meyer)

Continue reading

Read the full report at NPR News

NPR News supplies a brief version of this story through its feed. Continue to the original publication for the complete report.

Read the original at NPR News